Who
Masaru Matsuda
Officer
Company insider
Files Form 4 as: See Remark, Arcutis Biotherapeutics; SVP, General Counsel, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 96
- Buys
- 2
- Sells
- 27
- Bought
- $19K
- Sold
- $5.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 10 Feb 2020
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $92K3,674 at $25.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $92K3,674 at $25.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $250K9,989 at $25.03 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $250K9,989 at $25.03 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $32K1,230 at $26.12 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $32K1,230 at $26.12 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $172K7,372 at $23.27 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $21K884 at $23.61 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $172K7,372 at $23.27 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $21K884 at $23.61 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $165K6,553 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $5,001193 at $25.91 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $51K1,987 at $25.70 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $165K6,553 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $5,001193 at $25.91 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $51K1,987 at $25.70 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $93K3,325 at $27.95 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,000 at $0.00 | filing |
News
Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stocktickerreport.com · 18 Sep 2026Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)ARQT · seekingalpha.com · 19 Oct 2026
1 headline in the last 90 days name Masaru Matsuda; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.